公司概覽
業務類別 Diagnostics & Research
業務概覽 Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ inthe office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
公司地址 One IDEXX Drive, Westbrook, ME, USA, 04092
電話號碼 +1 207 556-0300
傳真號碼 +1 207 556-4346
公司網頁 https://www.idexx.com
員工數量 11000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Michael G. Erickson, PhD Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine -- 13/01/2026
Mr. Andrew J. Emerson Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer -- 20/02/2026
Mr. George J. Fennell Executive Vice President, Global CAG Commercial -- 28/03/2025
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 美元 1.12M 13/01/2026
Dr. Martin Alexander Smith, PhD Executive Vice President, Global Operations and Research and Development 美元 576.64K 28/03/2025
Ms. Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary -- 28/03/2025
Mr. Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology 美元 576.64K 28/03/2025
Dr. Nimrata Khatra Hunt, PhD Executive Vice President, Global Strategy and Commercial 美元 576.64K 28/03/2025
Mr. Michael Schreck Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience -- 28/03/2025
Mr. Michael P. Johnson Senior Vice President and Chief Human Resources Officer -- 28/03/2025
 
董事會成員
董事會 職務 更新日期
Mr. Bruce L. Claflin Independent Director 20/02/2026
Mr. Daniel M. Junius Independent Director 20/02/2026
Ms. M. Anne Szostak Independent Director 13/02/2026
Mr. Lawrence D. Kingsley Non-Executive Chairman of the Board 20/02/2026
Dr. Sophie V. Vandebroek, PhD Independent Director 20/02/2026
Mr. Stuart M. Essig, PhD Independent Director 20/02/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 13/01/2026
Mr. Sam A. Samad Independent Director 20/02/2026
Mr. Joseph L. Hooley Independent Director 20/02/2026
Ms. Karen A. Peacock Independent Director 20/02/2026
Ms. Irene Chang Britt Independent Director 20/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:18)
代號 名稱 佔比% 持有日期
FHLCFidelity MSCI Health Care ETF0.04%28/02/2026
SUSAiShares ESG Optimized MSCI USA ETF0.04%28/02/2026
QLDProShares Ultra QQQ0.04%27/02/2026
AVUSAvantis US Equity ETF0.04%28/02/2026
PWBInvesco Large Cap Growth ETF0.03%27/02/2026
NUMGNuveen ESG Mid-Cap Growth ETF0.03%27/02/2026
ACWIiShares MSCI ACWI ETF0.03%28/02/2026
FXHFirst Trust Health Care AlphaDEX® ETF0.03%26/02/2026
FLQMFranklin US Mid Cap Mltfctr Idx ETF0.03%28/02/2026
DFUSDimensional US Equity Market ETF0.03%27/02/2026
IWViShares Russell 3000 ETF0.03%28/02/2026
GFLWVictoryShares Free Cash Flow Growth ETF0.02%27/02/2026
ONEQFidelity Nasdaq Composite ETF0.02%27/02/2026
GARPiShares MSCI USA Quality GARP ETF0.02%28/02/2026
ESGVVanguard ESG US Stock ETF0.02%31/01/2026
RSPHInvesco S&P 500® Equal Wt Hlth Care ETF0.02%27/02/2026
FCTESMI 3Fourteen Full-Cycle Trend ETF0.02%27/02/2026
QQQEDirexion NASDAQ-100® Equal Wtd ETF0.02%26/02/2026
DFAUDimensional US Core Equity Market ETF0.02%27/02/2026
SPTMState StreetSPDRPortS&P1500CompStkMktETF0.02%27/02/2026
  1    2   3    4    5    6    7    8    9    10    11    12    13    14    15    16  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.